ATE478148T1 - Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine - Google Patents
Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteineInfo
- Publication number
- ATE478148T1 ATE478148T1 AT07002409T AT07002409T ATE478148T1 AT E478148 T1 ATE478148 T1 AT E478148T1 AT 07002409 T AT07002409 T AT 07002409T AT 07002409 T AT07002409 T AT 07002409T AT E478148 T1 ATE478148 T1 AT E478148T1
- Authority
- AT
- Austria
- Prior art keywords
- molecules
- acute phase
- tif
- inhibit
- induction
- Prior art date
Links
- 102000011767 Acute-Phase Proteins Human genes 0.000 title abstract 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 title abstract 2
- 102100030703 Interleukin-22 Human genes 0.000 title 2
- 108010054016 IL-TIF IL-10-related T cell-derived inducible factor Proteins 0.000 title 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 title 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 title 1
- 239000002876 beta blocker Substances 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 108010074109 interleukin-22 Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000000585 Interleukin-9 Human genes 0.000 abstract 1
- 108010002335 Interleukin-9 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229940118526 interleukin-9 Drugs 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62661700A | 2000-07-27 | 2000-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478148T1 true ATE478148T1 (de) | 2010-09-15 |
Family
ID=24511131
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07002409T ATE478148T1 (de) | 2000-07-27 | 2001-06-27 | Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine |
| AT01952260T ATE365801T1 (de) | 2000-07-27 | 2001-06-27 | Modulierung durch il-tif/interleukin-21 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01952260T ATE365801T1 (de) | 2000-07-27 | 2001-06-27 | Modulierung durch il-tif/interleukin-21 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1806404B1 (enExample) |
| JP (1) | JP4113773B2 (enExample) |
| CN (3) | CN100497628C (enExample) |
| AT (2) | ATE478148T1 (enExample) |
| AU (1) | AU7303301A (enExample) |
| CA (1) | CA2416820A1 (enExample) |
| DE (2) | DE60142861D1 (enExample) |
| ES (1) | ES2349312T3 (enExample) |
| WO (1) | WO2002010393A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US20030170823A1 (en) | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
| US20030012788A1 (en) | 2000-07-27 | 2003-01-16 | Jean-Christophe Renauld | Method for influencing kinase pathways with IL-22 |
| US20030023033A1 (en) * | 2001-07-26 | 2003-01-30 | Laure Dumoutier | Novel class II cytokine receptors and uses thereof |
| ES2277947T3 (es) * | 2000-10-13 | 2007-08-01 | Eli Lilly And Company | Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades. |
| US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| WO2003083062A2 (en) | 2002-03-22 | 2003-10-09 | Zymogenetics, Inc. | Anti-il-tif antibodies and methods of using in inflammation |
| AU2003251633A1 (en) | 2002-07-01 | 2004-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Il-21 as a regulator of immunoglobin production |
| CA2497661A1 (en) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the diagnosis of immune related diseases using pro71061 |
| US20060177421A1 (en) * | 2002-10-11 | 2006-08-10 | Novo Nordisk A/S | Treatment of allergic conditions by use of il 21 |
| EP1553970A1 (en) * | 2002-10-11 | 2005-07-20 | Novo Nordisk A/S | Treatment of allergic conditions by use of il 21 |
| ATE490275T1 (de) * | 2003-06-23 | 2010-12-15 | Genetics Inst Llc | Antikörper gegen interleukin-22 und verwendungen dafür |
| EP3006466B1 (en) | 2005-12-02 | 2018-08-01 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| IT1404858B1 (it) | 2011-02-21 | 2013-12-09 | Milano Politecnico | Supporto anti-sismico. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843697A (en) | 1996-07-17 | 1998-12-01 | University Of Medicine And Dentistry Of New Jersey | Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein |
| DE19848683B4 (de) | 1998-10-22 | 2004-05-06 | Basf Ag | Verbundschichtplatte |
| JP3769189B2 (ja) * | 1998-10-26 | 2006-04-19 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ｔ細胞誘導性因子（ｔｉｆ）をコードする単離された核酸分子、コードされたタンパク質およびその使用 |
| EP1177312B1 (en) * | 1999-04-28 | 2007-10-31 | Genetics Institute, LLC | Human gil-19/ae289 proteins and polynucleotides encoding same |
| WO2000073457A1 (en) * | 1999-05-27 | 2000-12-07 | Schering-Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
| CA2393369A1 (en) * | 1999-12-03 | 2001-06-07 | Zymogenetics, Inc. | Human cytokine receptor |
-
2001
- 2001-06-27 AT AT07002409T patent/ATE478148T1/de not_active IP Right Cessation
- 2001-06-27 CN CNB2005101169978A patent/CN100497628C/zh not_active Expired - Fee Related
- 2001-06-27 CN CNB018131255A patent/CN100448994C/zh not_active Expired - Fee Related
- 2001-06-27 EP EP07002409A patent/EP1806404B1/en not_active Expired - Lifetime
- 2001-06-27 AU AU7303301A patent/AU7303301A/xx not_active Withdrawn
- 2001-06-27 AT AT01952260T patent/ATE365801T1/de not_active IP Right Cessation
- 2001-06-27 JP JP2002516309A patent/JP4113773B2/ja not_active Expired - Fee Related
- 2001-06-27 EP EP01952260A patent/EP1305419B1/en not_active Expired - Lifetime
- 2001-06-27 DE DE60142861T patent/DE60142861D1/de not_active Expired - Lifetime
- 2001-06-27 ES ES07002409T patent/ES2349312T3/es not_active Expired - Lifetime
- 2001-06-27 CA CA002416820A patent/CA2416820A1/en not_active Abandoned
- 2001-06-27 DE DE60129137T patent/DE60129137D1/de not_active Expired - Lifetime
- 2001-06-27 CN CNA2008101764854A patent/CN101423551A/zh active Pending
- 2001-06-27 WO PCT/US2001/020485 patent/WO2002010393A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004504842A (ja) | 2004-02-19 |
| WO2002010393A2 (en) | 2002-02-07 |
| CA2416820A1 (en) | 2002-02-07 |
| WO2002010393A3 (en) | 2003-01-30 |
| CN100448994C (zh) | 2009-01-07 |
| EP1305419B1 (en) | 2007-06-27 |
| CN101423551A (zh) | 2009-05-06 |
| JP4113773B2 (ja) | 2008-07-09 |
| CN100497628C (zh) | 2009-06-10 |
| EP1305419A2 (en) | 2003-05-02 |
| CN1443241A (zh) | 2003-09-17 |
| ATE365801T1 (de) | 2007-07-15 |
| CN1796558A (zh) | 2006-07-05 |
| EP1806404A1 (en) | 2007-07-11 |
| AU7303301A (en) | 2002-02-13 |
| ES2349312T3 (es) | 2010-12-29 |
| DE60142861D1 (de) | 2010-09-30 |
| DE60129137D1 (de) | 2007-08-09 |
| EP1806404B1 (en) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE478148T1 (de) | Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine | |
| DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| CY1112101T1 (el) | Νευροτροφικοι παραγοντες | |
| CY1121580T1 (el) | ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| CY1108175T1 (el) | ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR | |
| SV2008002972A (es) | Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv | |
| MX2022000367A (es) | Heterodimeros, metodos y uso de los mismos. | |
| ATE500323T1 (de) | Subtilisin-variante | |
| DK1257648T3 (da) | Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein | |
| ATE491722T1 (de) | Herstellung und reinigung von il-29 | |
| EP1503795A4 (en) | USE OF STRESS PROTEINS TO IMPROVE THE EFFICIENCY OF THERAPEUTIC ANTIBODIES | |
| ATE348633T1 (de) | Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen | |
| DE60232120D1 (de) | Verfahren zur Herstellung von L-Lysin oder L-Arginin unter Verwendung methanolassimilierender Bakterien | |
| ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| ATE408624T1 (de) | Verfahren zur reinigung von fsh | |
| WO2006116181A3 (en) | Regulatory t cell mediator proteins and uses thereof | |
| DE60101851D1 (de) | Verfahren zur herstellung von platinmaterial verstärkt mittels fein verteilter oxide. | |
| WO2001040313A3 (en) | Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof | |
| ATE191568T1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
| DK1387854T3 (da) | SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf | |
| AR022150A1 (es) | Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados | |
| ATE350387T1 (de) | Verfahren zur reinigung von molekülen unter verwendung von unverzweigten alkyldiolen mit einständigen hydroxylgruppen | |
| DE602006009901D1 (de) | Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin | |
| EP1358207A4 (en) | REFUSION: USE OF GP64-6HIS TO CATALYZE MEMBRANE FUSION | |
| DE60108105D1 (de) | Verfahren zur Herstellung von 5-substituierten Isobenzofuranen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |